ATE95698T1 - Verhinderung von entzugserscheinungen. - Google Patents
Verhinderung von entzugserscheinungen.Info
- Publication number
- ATE95698T1 ATE95698T1 AT90403284T AT90403284T ATE95698T1 AT E95698 T1 ATE95698 T1 AT E95698T1 AT 90403284 T AT90403284 T AT 90403284T AT 90403284 T AT90403284 T AT 90403284T AT E95698 T1 ATE95698 T1 AT E95698T1
- Authority
- AT
- Austria
- Prior art keywords
- radical
- aryl
- alkyl
- hydrogen atom
- image
- Prior art date
Links
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 title abstract 2
- -1 alkyl radical Chemical class 0.000 abstract 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 150000003254 radicals Chemical class 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical class [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 150000001557 benzodiazepines Chemical class 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003529 diazepam Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Flanged Joints, Insulating Joints, And Other Joints (AREA)
- Compounds Of Unknown Constitution (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Surgical Instruments (AREA)
- Paper (AREA)
- Lubricants (AREA)
- Ceramic Products (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8915316A FR2654621B1 (fr) | 1989-11-22 | 1989-11-22 | Inhibition du syndrome d'abstinence. |
| EP90403284A EP0429360B1 (de) | 1989-11-22 | 1990-11-21 | Verhinderung von Entzugserscheinungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE95698T1 true ATE95698T1 (de) | 1993-10-15 |
Family
ID=9387643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90403284T ATE95698T1 (de) | 1989-11-22 | 1990-11-21 | Verhinderung von entzugserscheinungen. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5162323A (de) |
| EP (1) | EP0429360B1 (de) |
| JP (1) | JPH0699309B2 (de) |
| KR (1) | KR950007230B1 (de) |
| AT (1) | ATE95698T1 (de) |
| AU (1) | AU628237B2 (de) |
| CA (1) | CA2030401C (de) |
| DE (1) | DE69003924T2 (de) |
| DK (1) | DK0429360T3 (de) |
| ES (1) | ES2034909A6 (de) |
| FR (1) | FR2654621B1 (de) |
| HU (1) | HU207797B (de) |
| NO (1) | NO905028L (de) |
| PT (1) | PT95949B (de) |
| RU (1) | RU2042674C1 (de) |
| ZA (1) | ZA909256B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681956A (en) * | 1990-12-28 | 1997-10-28 | Neurogen Corporation | 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands |
| US5656762A (en) * | 1990-12-28 | 1997-08-12 | Neurogen Corporation | 4-piperidino-and piperazinomethyl-2-phenylimidazole derivatives, dopamine receptor subtype specific ligands |
| FR2671972B1 (fr) * | 1991-01-25 | 1995-03-03 | Esteve Labor Dr | Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives. |
| FR2701260B1 (fr) * | 1993-02-05 | 1995-05-05 | Esteve Labor Dr | Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments. |
| FR2705098B1 (fr) * | 1993-05-10 | 1995-08-04 | Esteve Labor Dr | Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) . |
| ES2099031B1 (es) * | 1995-05-31 | 1997-12-01 | Esteve Labor Dr | Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen. |
| US6166205A (en) * | 1998-09-02 | 2000-12-26 | Neurogen Corporation | 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands |
| FR2797399B1 (fr) | 1999-08-13 | 2002-10-18 | Aventis Pharma Sa | Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines |
| ES2167276B1 (es) * | 2000-10-20 | 2003-04-01 | Esteve Labor Dr | Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. |
| EP1749525A1 (de) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Zusammensetzung enthaltend substituierte Pyrazoline und gegen Sucht wirksame Mittel |
| WO2007009691A2 (en) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A. | Combination of substituted pyrazolines and anti -addictive agent |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4777173A (en) * | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
| FR2642759B1 (fr) * | 1989-02-09 | 1991-05-17 | Laboratorios Esteve Sa | Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante |
-
1989
- 1989-11-22 FR FR8915316A patent/FR2654621B1/fr not_active Expired - Fee Related
-
1990
- 1990-11-19 ZA ZA909256A patent/ZA909256B/xx unknown
- 1990-11-19 US US07/615,257 patent/US5162323A/en not_active Expired - Fee Related
- 1990-11-20 AU AU66767/90A patent/AU628237B2/en not_active Ceased
- 1990-11-20 NO NO90905028A patent/NO905028L/no unknown
- 1990-11-21 DK DK90403284.4T patent/DK0429360T3/da active
- 1990-11-21 AT AT90403284T patent/ATE95698T1/de not_active IP Right Cessation
- 1990-11-21 PT PT95949A patent/PT95949B/pt active IP Right Grant
- 1990-11-21 DE DE90403284T patent/DE69003924T2/de not_active Expired - Fee Related
- 1990-11-21 ES ES9002951A patent/ES2034909A6/es not_active Expired - Fee Related
- 1990-11-21 CA CA002030401A patent/CA2030401C/fr not_active Expired - Fee Related
- 1990-11-21 HU HU907230A patent/HU207797B/hu not_active IP Right Cessation
- 1990-11-21 EP EP90403284A patent/EP0429360B1/de not_active Expired - Lifetime
- 1990-11-22 JP JP2320509A patent/JPH0699309B2/ja not_active Expired - Lifetime
- 1990-11-22 KR KR1019900019028A patent/KR950007230B1/ko not_active Expired - Fee Related
-
1991
- 1991-10-15 RU SU915001669A patent/RU2042674C1/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| FR2654621A1 (fr) | 1991-05-24 |
| KR910009268A (ko) | 1991-06-28 |
| DK0429360T3 (da) | 1993-12-13 |
| NO905028L (no) | 1991-05-23 |
| HU907230D0 (en) | 1991-05-28 |
| ES2034909A6 (es) | 1993-04-01 |
| HUT56093A (en) | 1991-07-29 |
| DE69003924T2 (de) | 1994-02-24 |
| EP0429360A3 (en) | 1991-09-25 |
| EP0429360A2 (de) | 1991-05-29 |
| EP0429360B1 (de) | 1993-10-13 |
| HU207797B (en) | 1993-06-28 |
| JPH0699309B2 (ja) | 1994-12-07 |
| JPH03176422A (ja) | 1991-07-31 |
| KR950007230B1 (ko) | 1995-07-07 |
| AU628237B2 (en) | 1992-09-10 |
| AU6676790A (en) | 1991-05-30 |
| CA2030401C (fr) | 2000-03-07 |
| US5162323A (en) | 1992-11-10 |
| ZA909256B (en) | 1991-10-30 |
| PT95949A (pt) | 1991-09-13 |
| FR2654621B1 (fr) | 1994-09-23 |
| NO905028D0 (no) | 1990-11-20 |
| CA2030401A1 (fr) | 1991-05-23 |
| RU2042674C1 (ru) | 1995-08-27 |
| DE69003924D1 (de) | 1993-11-18 |
| PT95949B (pt) | 1998-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200000592A1 (ru) | Азаполициклические соединения, конденсированные с арилом | |
| NZ231983A (en) | Substituted 1,3-diazoles and 1,2,4-triazoles; fungicidal compositions, methods for preparation and combating fungal disease | |
| ATE95698T1 (de) | Verhinderung von entzugserscheinungen. | |
| ATE73790T1 (de) | Amino 5,6,7,8tetrahydronaphtho(2,3b>furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
| FR2665161B1 (fr) | Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments. | |
| KR950701332A (ko) | 세로토닌 5HT₂길항제로서의 4-이미도메틸-1-[2'페닐-2'옥소에틸-]피페리딘, 이의 제조방법 및 치료에서의 용도(4-Imidomethyl-1-[2'phenyl-2'oxoethyl-] piperidines as serotonin 5HT₂-antagonists, their preparation and use in therapy) | |
| DE69418744D1 (de) | Verwendung von Pregnanderivaten zur Behandlung von Tumoren | |
| ATE37533T1 (de) | Derivate der 4-phenyl-4-oxo-buten-2-saeure, verfahren zu ihrer herstellung, medikamente und mischungen mit diesen derivaten. | |
| AU539177B2 (en) | Amino alkoxy pyrazoles | |
| DE3669514D1 (de) | Neue anthracycline und diese enthaltende arzneimittel. | |
| ZA903944B (en) | Pyrrolidone derivatives the process for their preparation and the pharmaceutical compositions containing them | |
| ES8604843A1 (es) | Un metodo para la preparacion de un derivado de acetileno | |
| DE3862660D1 (de) | 2,3-dihydro-2-oxo-3-benzofuranyl-essigsaeurederivate und diese enthaltende arzneimittel. | |
| KR910006292A (ko) | 방향족 산의 n-아자비시클로 [3.3.0] 옥탄 아미드 | |
| ATE56442T1 (de) | 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
| HUT50833A (en) | Process for producing indolo/3,2-1-de/ /1,4/-oxazino/2,3,4-ij/ /1,5/-naphthyridine derivatives | |
| ATE53839T1 (de) | 2,3-dihydro-3-phenyl-benzofuran-2-onacetamidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
| HU906462D0 (en) | Process for producing substituted 20,21-dinoreburnamenine | |
| DE69002217D1 (de) | Dibenzodioxazecin- und dibenzodioxaazacycloundecin-derivate. | |
| IT1264978B1 (it) | Piridotiazine e piridotiazepine ad attivita' antiasmatica | |
| MX9708830A (es) | Compuestos de tetralin con actividad de resistencia a varios farmacos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |